在帕金森病中使用阿波摩芬的25年经验:现实生活中的长期回顾性耐受性研究
Sina R Potel1,2, Maria Chondrogiorgi2,3, Andrea Gozzi2,4
1Division of Neurology, Saint-Brieuc Hospital, Rennes University, Saint-Brieuc, France.
Journal of Parkinson's disease
|June 16, 2025
概括
对于晚期帕金森病 (PD) 的持续皮下阿波莫尔芬输液 (CSAI) 显示了45.7%的停药率,通常是在第一年内. 停止CSAI的关键预测因素包括治疗持续时间和基线运动分数.
科学领域:
- 神经学 神经学
- 运动障碍 运动障碍
- 药理学 药理学是指药理学的学科.
背景情况:
- 持续的皮下阿波莫芬输液 (CSAI) 是高级帕金森病 (PD) 运动波动的标准治疗方法.
- 关于CSAI耐受性和停药的长期数据有限,需要进一步调查.
研究的目的:
- 评估长期耐受性和确定CSAI中断的预测因子,在一个大规模的,单中心队列的晚期PD患者.
- 分析中止率,原因,不良事件和影响CSAI延续的因素.
主要方法:
- 在1999年至2023年期间连续接受CSAI的PD患者的回顾性分析.
- 收集的数据包括CSAI持续时间,不同时间段的停药率,人口统计信息,MDS-UPDRS运动分数,不良事件 (AE) 和停药原因.
- 后勤回归被用来确定CSAI停止的预测因素.
主要成果:
- 在208名患者中,45.7%的患者在平均8.0个月后停止使用CSAI,60%的患者在第一年内停止使用.
- 停药的主要原因是切换到深度大脑刺激 (44.2%) 和感知效率低 (15.8%).
- 79.8%的患者报告了不良事件,最常见的是幻觉 (41.3%) 和皮下结节 (24.0%). CSAI持续时间和基线非药物MDS-UPDRS运动得分是停止治疗的重要预测因素.
结论:
- CSAI的停药率很高,特别是在第一年内,受治疗持续时间和基线运动严重程度等因素的影响.
- 了解这些预测因素可以帮助临床医生选择患者,积极管理不良事件,并预测治疗寿命.
- 对优化CSAI治疗和患者选择的进一步研究是有必要的.
相关概念视频
01:24Parkinson's Disease: Treatment
391
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
391
01:25Analgesia and Pain Management
823
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
823
01:35Long-term Potentiation
55.9K
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre- and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
55.9K